Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy

NCT01484860 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01484860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01484860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2012
Completion date
August 31, 2013
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, metastatic disease